Market Place
Sourcing Support
Puma Bio To Host Call On Q1 2026 Financial Results
23 Apr 2026 //
PHARMIWEB
Puma Bio Reports Inducement Awards Under Nasdaq LR 5635(c)(4)
02 Apr 2026 //
BUSINESSWIRE
Puma Biotech Presents at TD Cowen`s 46th Health Care Conference
23 Feb 2026 //
BUSINESSWIRE
Puma Bio To Host Conference On Q4 & Full Year 2025 Finances
12 Feb 2026 //
BUSINESSWIRE
Puma Bio Discloses Inducement Awards Per Nasdaq LR 5635(C)(4)
05 Feb 2026 //
PHARMIWEB
Puma Bio Discloses Inducement Awards Per Nasdaq LR 5635(C)(4)
04 Feb 2026 //
BUSINESSWIRE
Puma Bio Discloses Inducement Awards Per Nasdaq LR 5635(C)(4)
07 Jan 2026 //
BUSINESSWIRE
Puma Biotechnology Added To The NASDAQ Biotechnology Index (NBI)
22 Dec 2025 //
BUSINESSWIRE
Puma Biotechnology Reports Third Quarter 2025 Financial Results
06 Nov 2025 //
BUSINESSWIRE
Puma Bio To Host Call On Q3 Financial Results
23 Oct 2025 //
BUSINESSWIRE
Puma Bio Discloses Inducement Awards Per Nasdaq LR 5635(C)(4)
02 Oct 2025 //
BUSINESSWIRE
Puma Bio Discloses Inducement Awards per Nasdaq LR 5635(c)(4)
04 Sep 2025 //
BUSINESSWIRE
Puma Biotech to Present at H.C. Wainwright Global Conference
02 Sep 2025 //
PHARMAWEB
Puma Bio Announces Inducement Awards Under Nasdaq Rule 5635(c)(4)
08 Aug 2025 //
BUSINESSWIRE
Puma Biotechnology Announces Q2 Financial Results
07 Aug 2025 //
BUSINESSWIRE
Puma to Host Q2 2025 Financial Results Call
24 Jul 2025 //
BUSINESSWIRE
Puma Bio Reports Inducement Awards Under Nasdaq Rule 5635(c)(4)
02 Jul 2025 //
BUSINESSWIRE
Puma Biotech Reports Inducement Awards Under Nasdaq LR 5635(c)(4)
04 Jun 2025 //
BUSINESSWIRE
Puma Biotechnology Reports First Quarter Financial Results
08 May 2025 //
BUSINESSWIRE
Puma Bio Reports Inducement Awards Under Nasdaq LR 5635(c)(4)
06 May 2025 //
BUSINESSWIRE
Er-Kim partners with Puma Biotech to distribute Nerlynx
30 Apr 2025 //
GLOBENEWSWIRE
Puma Biotech Presents Neratinib Data at AACR Meeting 2025
28 Apr 2025 //
BUSINESSWIRE
Puma Biotechnology to Discuss First Quarter 2025 Results
24 Apr 2025 //
BUSINESSWIRE
Puma Biotech Reports Inducement Awards Under Nasdaq LR 5635(c)(4)
03 Apr 2025 //
BUSINESSWIRE
Puma to Present Neratinib Data at AACR Annual Meeting 2025
26 Mar 2025 //
BUSINESSWIRE
Puma Biotechnology to Present at Barclays Healthcare Conference
05 Mar 2025 //
BUSINESSWIRE
Puma Biotech Reports Inducement Awards Under Nasdaq LR 5635(c)(4)
05 Mar 2025 //
BUSINESSWIRE
Puma Biotech Reports Q4 and Full Year 2024 Financial Results
27 Feb 2025 //
BUSINESSWIRE
Puma Biotech To Present At TD Cowen Health Care Conference
26 Feb 2025 //
BUSINESSWIRE
Puma Biotech to Host Conference Call to Discuss Q4 & Results
13 Feb 2025 //
BUSINESSWIRE
Puma Biotech Reports Inducement Awards Under Nasdaq LR 5635(c)(4)
05 Feb 2025 //
BUSINESSWIRE
Puma Biotech Reports Inducement Awards Under Nasdaq LR 5635(c)(4)
03 Jan 2025 //
BUSINESSWIRE
Puma’s NERLYNX® Included in NCCN Guidelines for Cervical Cancer
23 Dec 2024 //
BUSINESSWIRE
Puma Biotech Reports Inducement Awards Under Nasdaq LR 5635(c)(4)
04 Dec 2024 //
BUSINESSWIRE
Puma Biotech Initiates ALISCA™-Breast1 Phase II Trial of Alisertib
20 Nov 2024 //
BUSINESSWIRE
Puma Biotechnology Reports Q3 2024 Financial Results
07 Nov 2024 //
BUSINESSWIRE
Puma Biotech Reports Inducement Awards Under Nasdaq LR 5635(c)(4)
05 Nov 2024 //
BUSINESSWIRE
Puma Biotechnology To Host Q3 Results Conference Call
24 Oct 2024 //
BUSINESSWIRE
Puma Biotechnology to Present at H.C. Wainwright Global Investment Conference
03 Sep 2024 //
BUSINESSWIRE
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule
06 Aug 2024 //
BUSINESSWIRE
Puma Biotechnology Reports Second Quarter Financial Results
01 Aug 2024 //
BUSINESSWIRE
Puma Biotechnology Schedules Q2 2024 Financial Results Call
18 Jul 2024 //
BUSINESSWIRE
Puma Biotechnology Reports Inducement Awards Under Nasdaq Rule 5635(c)(4)
02 Jul 2024 //
BUSINESSWIRE
Puma Biotechnology to Join Russell 3000 Index
28 May 2024 //
BUSINESSWIRE
Puma Biotech Q1 2024 results call
18 Apr 2024 //
BUSINESSWIRE
Puma Biotech Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
03 Apr 2024 //
BUSINESSWIRE
Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib
11 Dec 2023 //
BUSINESSWIRE
Puma Biotech Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
06 Nov 2023 //
BUSINESSWIRE
Puma Announces Presentation of Findings from a Phase I/II Study of Alisertib
14 Oct 2023 //
BUSINESSWIRE
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule
05 May 2023 //
BUSINESSWIRE
Puma Biotechnology’s NERLYNX Included in NCCN Clinical Practice Guidelines
01 Feb 2023 //
BUSINESSWIRE
Puma Biotech to Present at B. Riley Securities’ 3rd Annual Oncology Conference
12 Jan 2023 //
BUSINESSWIRE
Puma Biotech Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
11 Jan 2023 //
BUSINESSWIRE
Puma Biotechnology Releases Updated Corporate Presentation
09 Jan 2023 //
BUSINESSWIRE
